Extensive evidence suggests that EGFR‐mutant cancer cells are a significant driver of immune suppression, actively shaping an immunosuppressive TME and impairing the quality of T cell‐mediated immune responses.[31, 34, 35, 36] Moreover, tumor‐associated DCs usually exhibit immature phenotypes and functional impairment, which severely compromise their ability to initiate effective anti‐tumor immunity. Here, EGFR is linked to neoplasm.